Compare Adaptive Biotechnologies Corp (ADPT) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Alphabet Inc Class A — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Alphabet Inc Class A trades at $361.67 (market cap $4.46T). The key difference: Alphabet Inc Class A is far larger — about 1339.3× Adaptive Biotechnologies Corp's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GOOGL | |
|---|---|---|
Market Cap | $3.33B | $4.46T |
Sector | Health | Media |
52-Week High | $22.37 | $402.62 |
52-Week Low | $10.24 | $174.36 |
Enterprise Value | $3.19B | $4.42T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Alphabet (GOOGL) trades at $361.92, down 1.24% on the day, with a bullish technical outlook from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 estimate. Revenue growth accelerated to $402.84 billion in 2025, while net income margins expanded to 32.8%. Positive sentiment is driven by AI advancements and YouTube subscription price increases announced on April 10, 2026.
The investment outlook remains favorable given Alphabet's dominant market position, AI-driven growth catalysts, and strong analyst support with an $431.35 price target. Key risks include antitrust scrutiny, as highlighted by the delayed Klarna case verdict on April 10, 2026, and competitive pressures in digital advertising. Institutional activity shows some selling, but the overall buy rating consensus of 85% underscores confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
